Ever since the passage of the Inflation Reduction Act (IRA), which gave the Centers for Medicare and Medicaid Services (CMS) the ability to negotiate maximum fair prices (MFP) for a selected group of ...

In the wake of the Food and Drug Administration’s (FDA’s) controversial decision to approve aducanumab for Alzheimer’s disease, how will, and how should, Medicare respond? We propose a coverage with ...